Alice Melão, MSc,  —

Novavax’s Lung Virus Vaccine Provokes Immune Response, Reduces COPD Hospitalizations, Trials Show

A vaccine that Novavax developed to deter the virus that causes most lung infections generated the desired immune response in children, and was safe, according to clinical trials. The trials dealt with the RSV F vaccine’s ability to protect older adults and children from the respiratory syncytial virus, or RSV. The…

Phase 3 Trial Demonstrates Improved Safety Profile of Revefenacin for Moderate to Very Severe COPD

Results of a Phase 3 trial of the investigational drug revefenacin (TD-4208) for the treatment of moderate to very severe chronic obstructive pulmonary disease (COPD) demonstrated the therapy is well tolerated and is associated with a lower incidence of adverse side effects compared to standard of care with Boehringer Ingelheim’s…

Pulmonary Structural Changes Regulate Lung Bacteria in COPD Patients, Study Finds

Severe cases of chronic obstructive pulmonary disease (COPD) can lead to structural changes in the lungs. These changes not only aggravate lung function, they can also alter the bacterial community (microbiome) that reside in the lungs, according to the results of a study published in the journal PLOS ONE.

COPD Patients with Non-Tuberculous Mycobacterial Pulmonary Disease Face Higher Mortality, Study Shows

Patients with chronic obstructive pulmonary disease (COPD) who also have non-tuberculous mycobacterial pulmonary disease (NTM-PD) are more likely to be hospitalized and die, according to a German study that urges improved care for this particular disease. The study,“Burden of non-tuberculous mycobacterial pulmonary disease in Germany,” appeared in the European…